Lexeo Therapeutics, Inc. Balance Sheet
LXEO|1 years of annual SEC 10-K data (FY2023-FY2023)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity. All figures from audited SEC 10-K filings.
Lexeo Therapeutics, Inc. had $140M in total assets with negative shareholders' equity of $113M as of FY2023.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.98 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2023 |
|---|---|
| Cash & Equivalents | $121.5M |
| Current Assets | $124.3M |
| PP&E (Net) | $1.1M |
| Total Assets | $139.8M |
| Current Liabilities | $17.2M |
| Shareholders' Equity | -$113.0M |